Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
72266-0125-10 72266-0125 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 2, 2019 In Use
72266-0126-01 72266-0126 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 15, 2019 In Use
72266-0126-10 72266-0126 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 2, 2019 In Use
82982-0059-10 82982-0059 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 28, 2023 In Use
00615-8441-39 00615-8441 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 10, 2022 In Use
00615-8441-10 00615-8441 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 7, 2023 In Use
00703-4502-04 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Dec. 1, 1991 In Use
00703-4502-93 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sept. 4, 2024 In Use
25021-0259-50 25021-0259 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
25021-0259-51 25021-0259 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
43602-0176-01 43602-0176 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 6, 2024 In Use
43602-0176-05 43602-0176 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 6, 2024 In Use
46708-0813-50 46708-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
46708-0813-63 46708-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
50090-7218-00 50090-7218 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7218-01 50090-7218 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7218-02 50090-7218 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7218-04 50090-7218 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7218-05 50090-7218 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7218-07 50090-7218 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7218-08 50090-7218 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7219-00 50090-7219 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50090-7219-01 50090-7219 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 13, 2024 In Use
50633-0220-04 50633-0220 Uridine triacetate VISTOGARD 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral July 31, 2024 In Use
50633-0220-20 50633-0220 Uridine triacetate VISTOGARD 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral July 31, 2024 In Use

Found 10,000 results in 7 milliseconds — Export these results